FundamentalVR, a Boston, MA-based medical simulation platform that combines virtual reality and haptics through data, artificial intelligence, and multimodal learning, raised USD20M in Series B funding.
The round was led by EQT Life Sciences and Downing Ventures. The new investments follow a Series A round in October 2019 and bring the company’s total funding to over $30 million. As part of the transactions, Drew Burdon of EQT Life Sciences will join the Board of Directors.
The company intends to use the funds for further development of HapticVRTM, the machine learning data insights product, and geographic expansion throughout the US.
Led by Chief Executive Richard Vincent, FundamentalVR delivers immersive multi-user simulations called ‘Blended VR’ underpinned with HapticVRTM interactions that enable medical devices and procedures to drive consistency and compliance across their training programs provided on the multimodal Fundamental Surgery platform. The platform allows for full rehearsal of medical and surgical procedures, providing deep data insight into competency and skills development, accelerating safe adoption across the board.
Deployed in over 30 countries, FundamentalVR’s high-fidelity simulations help life science, pharmaceutical, and med-device companies deploy medical innovations in disciplines from ophthalmology to robotics, gene therapy, and more.